A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
Part of paid clinical trials in Tempe, Arizona.
- Sponsor
- Merck Sharp & Dohme LLC
- Study ID
- NCT07300280
- Phase
- PHASE1
- Status
- Active Not Recruiting
Conditions
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- MK-0616A — DRUGEnlicitide/rosuvastatin fixed dose combination (FDC) or enlicitide/rosuvastatin FDC formulation B oral tablets
- Enlicitide — DRUGOral tablet
- Rosuvastatin — DRUGOral tablet
Study Details
This goal of this trial is to learn about two medicines, enlicitide and rosuvastatin, in healthy people. Researchers will compare the amounts of enlicitide and rosuvastatin in a person's body over time, when they are given as separate medicines and when they are combined into one tablet.
Key Dates
- First listed
- Dec 23, 2025
- Start date
- Dec 29, 2025
- Status verified
- Sep 2026
- Primary completion
- Oct 14, 2026
- Completion
- Oct 21, 2026
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Enlicitide + Rosuvastatin Part 1Participants in Part 1 will receive a single dose of enlicitide tablet coadministered with a single dose of rosuvastatin tablet
- Experimental: MK-0616A Part 1Participants in Part 1 will receive a single dose of MK-0616A
- Experimental: Enlicitide + Rosuvastatin Part 2Participants in Part 2 will receive a single dose of enlicitide tablet coadministered with a single dose of rosuvastatin tablet
- Experimental: MK-0616A Part 2Participants in Part 2 will receive a single dose of MK-0616A formulation B
Primary Outcome Measure
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Enlicitide [ Time Frame: Pre dose and at designated time points up to 168 hours post dose ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Celerion ( Site 0001) | Tempe | Arizona | 85283 | - |
Find similar trials in Tempe, AZ
By research site
Related Studies
- A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut DysbiosisRecruiting · Mayo Clinic · Scottsdale, Arizona
- A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's DiseaseRecruiting · Mayo Clinic · Scottsdale, Arizona
- Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXARecruiting · Alphatec Spine, Inc. · Phoenix, Arizona
- Increasing Physical Activity Through Social Support and Stress ResilienceRecruiting · Arizona State University · Phoenix, Arizona